Mucoadhesive Peptide Nanoantioxidants for Mucosal Wound Care

Self-assembling CR8L10@CAT nanoantioxidants anchor catalase to mucin via disulfide bonds, overcoming the clearance barrier in topical and mucosal wound.

Published 2026-08-14 | Clinical education for wound care physicians, podiatrists, nurses, and wound-center medical directors
By Josh Fathi, Founder, NextGen Biologics
Reviewed by the NextGen Biologics clinical editorial team against cited sources
This content is informational and not medical advice; it is not a substitute for professional diagnosis or treatment.

Mucoadhesive Peptide Nanoantioxidants for Mucosal Wound Care: Disulfide-Anchored Drug Delivery

The hardest problem in topical wound-care biologic delivery is keeping the therapeutic agent at the wound site long enough to act. Physiological clearance mechanisms — mucus turnover, enzymatic degradation, fluid washout — strip away topically applied peptides and growth factors before they reach therapeutic concentrations [3,4]. This clearance barrier is especially acute in mucosal and moist wound environments: oral cavities, peristomal skin, chronic draining wounds.

A preclinical study in Advanced Science introduces an engineering solution: a self-assembling peptide that anchors its payload to mucin via reversible disulfide bonds, converting a transient application into a sustained-release depot [1]. The platform demonstrated efficacy in interstitial cystitis/bladder pain syndrome (IC/BPS) and acute lung injury (ALI) — disease models that share wound care's clearance-dominated pharmacokinetic problem [1]. This article examines the delivery mechanism and its translational relevance for mucosal wound-care biologics.

The Clearance Problem in Mucosal and Moist Wound Environments

Reactive oxygen species serve a dual role in wound biology. At controlled levels, they coordinate the inflammatory phase — recruiting neutrophils, activating antimicrobial defenses, initiating the transition to proliferation [2]. In chronic wounds, sustained oxidative stress overwhelms endogenous antioxidant defenses: catalase and superoxide dismutase activity cannot neutralize continuous ROS production from inflammatory cells and ischemic-reperfused tissue [2,3]. Excess ROS degrades extracellular matrix, inhibits keratinocyte migration, and perpetuates the pro-inflammatory macrophage phenotype that blocks progression to proliferation [3,4].

Lobmann et al. documented the downstream consequence: diabetic wounds exhibit markedly elevated matrix metalloproteinase expression, degrading granulation tissue as quickly as it forms [5]. Topically applied biologics face the same environment — proteolytic degradation and fluid washout reduce residence time to minutes or hours [3,4].

CR8L10@CAT: Self-Assembly and Disulfide-Mucin Anchoring

Li et al. describe CR8L10@CAT, a nanocomplex self-assembled from a cysteine-modified short peptide (CR8L10) and catalase (CAT), the endogenous enzyme that decomposes hydrogen peroxide into water and oxygen [1]. Self-assembly produces nanoscale complexes with a cysteine-rich surface — the functional basis for mucoadhesion.

The anchoring mechanism is biochemically distinct from conventional mucoadhesive polymers. Rather than relying on electrostatic interaction or physical entanglement — both disrupted by mucus shedding — CR8L10's surface cysteine residues form dynamic covalent disulfide bonds with cysteine-rich domains in mucin glycoproteins [1]. This thiol-disulfide exchange is the same chemistry thiolated polymers exploit, where introducing free thiol groups onto polymer backbones increases mucoadhesive strength several-fold [6,7]. The disulfide bond is reversible — it does not permanently modify tissue — but resists clearance long enough to establish a sustained-release depot.

Once anchored, CR8L10@CAT actively scavenges ROS at the delivery site, continuously decomposing hydrogen peroxide as it diffuses from the depot into underlying tissue [1]. This active-scavenging distinguishes the nanoantioxidant platform from passive wound-covering approaches.

Preclinical Evidence in Mucosal Disease Models

In the IC/BPS model, intravesically administered CR8L10@CAT achieved urine-resistant bladder retention far exceeding unmodified catalase, maintaining therapeutic enzyme presence despite continuous urine production and voiding. Treated animals showed ROS elimination in the bladder mucosa, inhibition of pro-inflammatory signaling, restoration of urothelial integrity, and significant alleviation of pain and voiding dysfunction — with better outcomes than clinically used intravesical agents [1].

In the ALI model, inhaled CR8L10@CAT achieved enhanced pulmonary retention and mitigated ROS-associated lung inflammation [1]. The pulmonary mucosa, with its continuous ciliary clearance, represents one of the most hostile environments for topical drug retention — yet disulfide-anchoring provided sufficient residence time for therapeutic effect.

Translational Relevance for Mucosal Wound Care

These results, obtained in non-wound indications, are directly relevant to the wound-care formulary question. Several wound environments share the mucin-rich, clearance-prone characteristics of bladder and lung mucosa: oral wounds (post-surgical sites, radiation mucositis) are continuously bathed in saliva; peristomal skin is exposed to enzymatic effluent; chronic draining wounds produce exudate that washes out topically applied agents within hours. In each, the limiting factor is not therapeutic potency but residence time.

The CR8L10@CAT platform addresses this through a mechanism that is, in principle, tissue-agnostic: any mucin-rich or thiol-containing surface can form the disulfide anchor [1,6]. The critical translational question is whether chronic wound beds express sufficient mucin or accessible thiol groups to support anchoring — requiring dedicated preclinical evaluation in wound-specific models. The active-scavenging function compounds the relevance: a platform that simultaneously anchors and continuously neutralizes excess ROS addresses two of the three major barriers to biologic wound therapy [2,3].

Regulatory and Translational Outlook

CR8L10@CAT is at the earliest preclinical stage. No human data exists. No clinical trials are registered. The anchoring mechanism has not been tested in human wound tissue or large-animal models. Key questions remain: whether chronic wound beds provide sufficient anchoring substrate, whether nanocomplexes can incorporate wound-specific biologics alongside catalase, and how the platform interacts with debridement and grafting protocols. The path to any clinical wound-care application is years away.

Clinical Bottom Line

For wound-care clinicians and biologic product evaluators, the mucoadhesive peptide nanoantioxidant platform is valuable as a drug-delivery concept, not as a therapy. It demonstrates that the clearance problem — the largest pharmacokinetic barrier to topical biologic efficacy in mucosal and moist wounds — has an engineering solution rooted in reversible covalent chemistry. Current practice should continue to rely on evidence-based protocols: thorough debridement, effective offloading, moisture management, and biologic grafting when standard care is insufficient [4]. The disulfide-anchored nanoantioxidant platform, if it progresses through clinical development, may eventually extend the residence time and therapeutic activity of wound-applied agents. Until then, it is emerging science — mechanistically important, clinically unproven, and not an approved therapy.

References

1. Li X, Ma Y, He D, et al. Mucoadhesive peptide-catalase self-assembled nano-formulation for effective treatment of mucosal inflammatory diseases. Adv Sci (Weinh). 2026 Jul 2:e76390. doi:10.1002/advs.76390. PMID: 42389877. 2. Dunnill C, Patton T, Brennan J, et al. Reactive oxygen species (ROS) and wound healing: the functional role of ROS and emerging ROS-modulating technologies for augmentation of the healing process. Int Wound J. 2017;14(1):89-96. doi:10.1111/iwj.12557. PMID: 26688157. 3. Raziyeva K, Kim Y, Zharkinbekov Z, et al. Immunology of acute and chronic wound healing. Biomolecules. 2021;11(5):700. doi:10.3390/biom11050700. PMID: 34066746. 4. Eming SA, Martin P. Wound repair and regeneration: mechanisms, signaling, and translation. Sci Transl Med. 2014;6(265):265sr6. doi:10.1126/scitranslmed.3009337. PMID: 25473038. 5. Lobmann R, Ambrosch A, Schultz G, et al. Expression of matrix metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia. 2002;45(7):1011-1016. doi:10.1007/s00125-002-0868-8. PMID: 12136400. 6. Hauptstein S, Bonengel S, Rohrer J, Bernkop-Schnurch A. Thiolated polymers: bioinspired polymers utilizing one of the most important bridging structures in nature. Adv Drug Deliv Rev. 2019;143:140-156. doi:10.1016/j.addr.2019.04.007. PMID: 31028759. 7. Bernkop-Schnurch A, Steininger S. Thiolated polymers: self-crosslinking properties of thiolated 450 kDa poly(acrylic acid) and their influence on mucoadhesion. Eur J Pharm Sci. 2002;15(5):457-462. doi:10.1016/s0928-0987(02)00030-6. PMID: 11988400.